Moderna COVID-19 Vaccine Trial Shows 94.1 Percent Efficacy

Eurasia Review

31 Dec 2020 0 shares 2 views

Moderna COVID-19 Vaccine Trial Shows 94.1 Percent Efficacy

Moderna COVID-19 Vaccine Trial Shows 94.1 Percent Efficacy

Eurasia Review

Published 31 Dec 2020

A peer-reviewed paper published in The New England Journal of Medicine provides data from the much-anticipated COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc. Results from the primary analysis of the study, which will continue for two years, provide evidence that the...

You might like

Related news coverage

America’s Deadliest Year, In Numbers – OpEd

America’s Deadliest Year, In Numbers – OpEd

Eurasia Review 30 Dec 2020

This year, more than any other in recent memory, we experienced a public health emergency in the shape of charts and data which..

Moderna COVID-19 vaccine shows 94.1% efficacy in trial: Study
Hindu 31 Dec 2020
COVID-19: Moderna vaccine shows 94.1 per cent efficacy in trial, according to study
DNA 31 Dec 2020
Moderna vaccine shows 94.1% efficacy in trial: Study
IndiaTimes 31 Dec 2020
AstraZeneca: ‘Winning’ vaccine formula is 100% effective against severe COVID-19
Upworthy 27 Dec 2020

Advertisement

More coverage

Chinese Sinovac covid vaccine more than 50% effective, but data withheld

Chinese Sinovac covid vaccine more than 50% effective, but data withheld

WorldNews 24 Dec 2020

A Covid-19 vaccine developed by Chinese pharmaceutical firm Sinovac Biotech Ltd. was found to be more than 50% effective in a..

BioNTech, Moderna say approved COVID-19 vaccines should protect against new strain
Proactive Investors 22 Dec 2020
Moderna COVID-19 vaccine described as highly effective by FDA scientists
Proactive Investors 15 Dec 2020
Starpharma’s COVID-19 nasal spray to be ready for market next quarter
Proactive Investors 14 Dec 2020
Moderna vaccine confers at least 3 months immunity: study
CTV News 03 Dec 2020